Abiomed (ABMD) 10-Q 6 Aug 14 2014 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Jun. 30, 2014	Jul. 31, 2014
Document Information [Line Items]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Jun-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q1	'
Trading Symbol	'ABMD	'
Entity Registrant Name	'ABIOMED INC	'
Entity Central Index Key	'0000815094	'
Current Fiscal Year End Date	'--03-31	'
Entity Filer Category	'Large Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	40,463,481

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Jun. 30, 2014	Mar. 31, 2014
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$34,740	$20,916
Short-term marketable securities	52,458	55,663
Accounts receivable, net	22,763	24,357
Inventories	13,920	13,948
Prepaid expenses and other current assets	3,334	3,082
Total current assets	127,215	117,966
Long-term marketable securities	33,760	41,761
Property and equipment, net	6,716	6,889
Goodwill	37,694	37,990
Other assets	801	801
Total assets	206,186	205,407
Current liabilities:	'	'
Accounts payable	6,759	7,746
Accrued expenses	17,015	17,899
Deferred revenue	5,200	4,766
Total current liabilities	28,974	30,411
Long-term deferred tax liability	6,640	6,415
Other long-term liabilities	222	228
Total liabilities	35,836	37,054
Commitments and contingencies (Note 9)	'	'
Stockholders' equity:	'	'
Class B Preferred Stock, $.01 par value Authorized - 1,000,000 shares; Issued and outstanding - none	0	0
Common stock, $.01 par value Authorized - 100,000,000 shares; Issued - 41,619,312 shares at June 30, 2014 and 41,122,695 shares at March 31, 2014; Outstanding - 40,365,369 shares at June 30, 2014 and 39,916,328 shares at March 31, 2014	415	411
Additional paid in capital	441,260	436,136
Accumulated deficit	-252,619	-250,910
Treasury stock at cost - 1,253,943 shares at June 30, 2014 and 1,206,367 shares at March 31, 2014	-17,567	-16,554
Accumulated other comprehensive loss	-1,139	-730
Total stockholders' equity	170,350	168,353
Total liabilities and stockholders' equity	$206,186	$205,407

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Jun. 30, 2014	Mar. 31, 2014
Class B Preferred Stock, par value	$0.01	$0.01
Class B Preferred Stock, Authorized	1,000,000	1,000,000
Class B Preferred Stock, Issued	0	0
Class B Preferred Stock, outstanding	0	0
Common stock, par value	$0.01	$0.01
Common stock, Authorized	100,000,000	100,000,000
Common stock, Issued	41,619,312	41,122,695
Common stock, Outstanding	40,365,369	39,916,328
Treasury stock, shares	1,253,943	1,206,367

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
Revenue:	'	'
Product revenue	$48,660	$42,609
Funded research and development	151	61
Total Revenue	48,811	42,670
Costs and expenses:	'	'
Cost of product revenue	9,689	8,723
Research and development	9,062	7,287
Selling, general and administrative	31,598	27,967
Costs and Expenses, Total	50,349	43,977
Loss from operations	-1,538	-1,307
Other income (loss):	'	'
Investment income, net	44	16
Other income (loss), net	11	-21
Nonoperating Income (Expense), Total	55	-5
Loss before income tax provision	-1,483	-1,312
Income tax provision	226	411
Net loss	($1,709)	($1,723)
Basic net loss per share	($0.04)	($0.04)
Basic weighted average shares outstanding	40,062	38,678
Diluted net loss per share	($0.04)	($0.04)
Diluted weighted average shares outstanding	40,062	38,678

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Comprehensive (Loss) Income (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
Net loss	($1,709)	($1,723)
Other comprehensive (loss) income:	'	'
Foreign currency translation (losses) gains	-436	526
Net unrealized gains (losses) on marketable securities	27	-21
Other comprehensive (loss) income	-409	505
Comprehensive loss	($2,118)	($1,218)

Condensed_Consolidated_Stateme2

Condensed Consolidated Statements of Cash Flows (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
Operating activities:	'	'
Net loss	($1,709)	($1,723)
Adjustments required to reconcile net income to net cash provided by operating activities:	'	'
Depreciation and amortization	621	652
Bad debt expense	31	15
Stock-based compensation	4,290	3,921
Write-down of inventory	206	207
Deferred tax provision	225	226
Changes in assets and liabilities:	'	'
Accounts receivable	1,548	1,971
Inventories	-234	-1,689
Prepaid expenses and other assets	-255	292
Accounts payable	-1,049	-1,302
Accrued expenses and other long-term liabilities	-919	-2,397
Deferred revenue	435	-206
Net cash provided by (used for) operating activities	3,190	-33
Investing activities:	'	'
Purchases of marketable securities	-24,524	-15,401
Proceeds from the sale and maturity of marketable securities	35,730	17,750
Purchase of other investment	'	-750
Purchases of property and equipment	-380	-711
Net cash provided by investing activities	10,826	888
Financing activities:	'	'
Proceeds from the exercise of stock options	820	1,931
Payments in lieu of issuance of common stock for minimum payroll taxes	-1,013	-426
Net cash (used for) provided by financing activities	-193	1,505
Effect of exchange rate changes on cash	1	-84
Net increase in cash and cash equivalents	13,824	2,276
Cash and cash equivalents at beginning of period	20,916	9,451
Cash and cash equivalents at end of period	34,740	11,727
Supplemental disclosures:	'	'
Cash paid for income taxes	172	798
Fixed asset expenditures incurred, not yet paid	$215	$86

Nature_of_Business_and_Basis_o

Nature of Business and Basis of Preparation	3 Months Ended
	Jun. 30, 2014
Nature of Business and Basis of Preparation	'
	Note 1. Nature of Business and Basis of Preparation
	Abiomed, Inc. (the “Company” or “Abiomed”) is a leading provider of mechanical circulatory support devices and offers a continuum of care in heart recovery to heart failure patients. The Company develops, manufactures and markets proprietary products that are designed to enable the heart to rest, heal and recover by improving blood flow and/or performing the pumping function of the heart. The Company’s products are used in the cardiac catheterization lab, or cath lab, by interventional cardiologists and in the heart surgery suite by heart surgeons for patients who are in need of hemodynamic support prophylactically or emergently before, during or after angioplasty or heart surgery procedures.
	The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles, or GAAP, for interim financial reporting and in accordance with Article 10 of Regulation S-X. Accordingly, they do not include all of the information and note disclosures required by GAAP for complete financial statements. These statements should be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2014 that has been filed with the Securities and Exchange Commission, or SEC.
	In the opinion of management, the accompanying unaudited consolidated financial statements include all adjustments, which are of a normal recurring nature, necessary for a fair presentation of results for the interim periods presented. The results of operations for any interim period may not be indicative of results for the full fiscal year.
	There have been no changes in the Company’s significant accounting policies for the three months ended June 30, 2014 as compared to the significant accounting policies described in the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2014 that has been filed with the SEC.
	Recent Accounting Pronouncements
	In May 2014, the Financial Accounting Standards Board issued Accounting Standards Update (ASU) 2014-09, Revenue from Contracts with Customers to provide updated guidance on revenue recognition. ASU 2014-09 requires a company to recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In doing so, companies may need to use more judgment and make more estimates than under today’s guidance. These may include identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. ASU 2014-09 is effective for the Company in the first quarter of fiscal 2017. Early adoption is not permitted. The Company is currently evaluating the impact of adopting ASU 2014-09 on its consolidated financial statements.

Net_Loss_Income_Per_Share

Net (Loss) Income Per Share	3 Months Ended
	Jun. 30, 2014
Net (Loss) Income Per Share	'
	Note 2. Net (Loss) Income Per Share
	Basic net (loss) income per share is computed by dividing net (loss) income by the weighted average number of common shares outstanding during the period. Diluted net (loss) income per share is computed by dividing net (loss) income by the weighted average number of dilutive common shares outstanding during the period. Diluted shares outstanding are calculated by adding to the weighted average shares outstanding any potential dilutive securities outstanding for the period. Potential dilutive securities include stock options, restricted stock awards, restricted stock units, performance-based stock awards and shares to be purchased under the Company’s employee stock purchase plan. In periods when a net loss is reported, all common stock equivalents are excluded from the calculation because they would have an anti-dilutive effect, meaning the loss per share would be reduced. Therefore, in periods when a loss is reported, basic and dilutive loss per share are the same. The Company’s basic and diluted net (loss) income per share for the three months ended June 30, 2014 and 2013 were as follows (in thousands, except per share data):
		Three Months Ended
		June 30,
		2014			2013
	Basic Net (Loss) Income Per Share
	Net loss	$	(1,709	)	$	(1,723	)
	Weighted average shares used in computing basic net loss per share		40,062			38,678
	Net loss per share - basic	$	(0.04	)	$	(0.04	)
		Three Months Ended
		June 30,
		2014			2013
	Diluted Net (Loss) Income Per Share
	Net loss	$	(1,709	)	$	(1,723	)
	Weighted average shares used in computing basic net loss per share		40,062			38,678
	Effect of dilutive securities		—			—
	Weighted average shares used in computing diluted net loss per share		40,062			38,678
	Net loss per share - diluted	$	(0.04	)	$	(0.04	)
	For the three months ended June 30, 2014, approximately 3,678,000 shares underlying stock options and approximately 1,242,000 restricted shares and restricted stock units were excluded from the calculation of diluted weighted average shares outstanding because the Company incurred a loss in the period and to include them would have been anti-dilutive.
	For the three months ended June 30, 2013, approximately 4,326,000 shares underlying stock options and approximately 1,168,000 restricted shares and restricted stock units were excluded from the calculation of diluted weighted average shares outstanding because the Company incurred a loss in the period and to include them would have been anti-dilutive.

Marketable_Securities_and_Fair

Marketable Securities and Fair Value Measurements	3 Months Ended
	Jun. 30, 2014
Marketable Securities and Fair Value Measurements	'
	Note 3. Marketable Securities and Fair Value Measurements
	Marketable Securities
	The Company’s marketable securities are classified as available-for-sale securities and, accordingly, are recorded at fair value. The difference between amortized cost and fair value is included in stockholders’ equity.
	The Company’s marketable securities at June 30, 2014 and March 31, 2014 are invested in the following:
		Amortized		Gross		Gross			Fair Market
		Cost		Unrealized		Unrealized			Value
				Gains		Losses
		(in $000’s)
	At June 30, 2014:
	US Treasury securities	$	19,486	$	—	$	—		$	19,486
	Short-term government-backed securities		32,963		11		(2	)		32,972
	Long-term government-backed securities		33,758		11		(9	)		33,760
		$	86,207	$	22	$	(11	)	$	86,218
		Amortized		Gross		Gross			Fair Market
		Cost		Unrealized		Unrealized			Value
				Gains		Losses
		(in $000’s)
	At March 31, 2014:
	US Treasury securities	$	31,487	$	—	$	—		$	31,487
	Short-term government-backed securities		24,174		6		(4	)		24,176
	Long-term government-backed securities		41,779		8		(26	)		41,761
		$	97,440	$	14	$	(30	)	$	97,424
	Fair Value Hierarchy
	Fair value is defined as the price that would be received upon the sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three categories:
	Level 1: Quoted market prices in active markets for identical assets or liabilities.
	Level 2: Observable market based inputs or unobservable inputs that are corroborated by market data.
	Level 3: Unobservable inputs that are not corroborated by market data.
	Level 1 primarily consists of financial instruments whose values are based on quoted market prices such as exchange-traded instruments and listed equities.
	Level 2 includes financial instruments that are valued using models or other valuation methodologies. These models are primarily industry-standard models that consider various assumptions, including time value, yield curve, volatility factors, prepayment speeds, default rates, loss severity, current market and contractual prices for the underlying financial instruments, as well as other relevant economic measures. Substantially all of these assumptions are observable in the marketplace, can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace.
	Level 3 is comprised of unobservable inputs that are supported by little or no market activity. Financial assets are considered Level 3 when their fair values are determined using pricing models, discounted cash flows or similar techniques and at least one significant model assumption or input is unobservable.
	The following table presents the Company’s financial instruments recorded at fair value in the consolidated balance sheet, classified according to the three categories described above:
		Level 1		Level 2		Level 3			Total
		(in $000’s)
	At June 30, 2014:
	U.S. Treasury securities		—	$	19,486		—		$	19,486
	Short-term government-backed securities		—		32,972		—			32,972
	Long-term government-backed securities		—		33,760		—			33,760
			—	$	86,218		—		$	86,218
		Level 1		Level 2		Level 3			Total
		(in $000’s)
	At March 31, 2014:
	U.S. Treasury securities		—	$	31,487		—		$	31,487
	Short-term government-backed securities		—		24,176		—			24,176
	Long-term government-backed securities		—		41,761		—			41,761
			—	$	97,424		—		$	97,424

Inventories

Inventories	3 Months Ended
	Jun. 30, 2014
Inventories	'
	Note 4. Inventories
	The components of inventories are as follows:
		June 30,		March 31,
		2014		2014
		(in $000’s)
	Raw materials and supplies	$	6,534	$	6,414
	Work-in-progress		6,295		6,261
	Finished goods		1,091		1,273
		$	13,920	$	13,948
	The Company’s inventories relate to its circulatory care product lines, primarily the Impella and AB5000 product platforms. Finished goods and work-in-process inventories consist of direct material, labor and overhead. The Company recorded $0.2 million in each of the three months ended June 30, 2014 and 2013, in write-downs of inventory.

Goodwill

Goodwill	3 Months Ended
	Jun. 30, 2014
Goodwill	'
	Note 5. Goodwill
	The carrying amount of goodwill at June 30, 2014 and March 31, 2014 was $37.7 million and $38.0 million, respectively, and has been recorded in connection with the Company’s acquisition of Impella Cardiosystems AG, or Impella, in 2005. The goodwill activity for the three months ended June 30, 2014 is as follows:
		(in $000’s)
	Balance at March 31, 2014	$	37,990
	Exchange rate impact		(296	)
	Balance at June 30, 2014	$	37,694

Accrued_Expenses

Accrued Expenses	3 Months Ended
	Jun. 30, 2014
Accrued Expenses	'
	Note 6. Accrued Expenses
	Accrued expenses consist of the following:
		June 30,		March 31,
		2014		2014
		(in $000’s)
	Employee compensation	$	11,798	$	11,967
	Research and development		1,403		1,587
	Sales and income taxes		1,215		1,445
	Professional, legal and accounting fees		998		1,304
	Warranty		813		794
	Other		788		802
		$	17,015	$	17,899
	Employee compensation consists primarily of accrued bonuses, accrued commissions and accrued employee benefits at June 30, 2014 and March 31, 2014.

StockBased_Compensation

Stock-Based Compensation	3 Months Ended
	Jun. 30, 2014
Stock-Based Compensation	'
	Note 7. Stock-Based Compensation
	The following table summarizes stock-based compensation expense by financial statement line item in the Company’s consolidated statements of operations for the three months ended June 30, 2014 and 2013:
		Three Months Ended
		June 30,
		2014			2013
		(in $000’s)
	Cost of product revenue	$	209		$	208
	Research and development		853			745
	Selling, general and administrative		3,228			2,968
		$	4,290		$	3,921
	The components of stock-based compensation for the three months ended June 30, 2014 and 2013 were as follows:
		Three Months Ended
		June 30,
		2014			2013
		(in $000’s)
	Restricted stock units and awards	$	3,420		$	2,936
	Stock options		799			925
	Employee stock purchase plan		71			60
		$	4,290		$	3,921
	Stock Options
	The following table summarizes the stock option activity for the three months ended June 30, 2014:
								Weighted
		Shares			Weighted			Average		Aggregate
		Underlying			Average			Remaining		Intrinsic
		Options			Exercise			Contractual		Value
		(in thousands)			Price			Term (years)		(in thousands)
	Outstanding at April 1, 2014		3,492		$	13.27			4.92
	Granted		256			21.55
	Exercised		(67	)		9.99
	Cancelled and expired		(3	)		17.67
	Outstanding at June 30, 2014		3,678		$	13.9			5.08	$	41,412
	Exercisable at June 30, 2014		2,938		$	11.93			4.11	$	38,802
	Options vested and expected to vest at June 30, 2014		3,614		$	13.78			5.01	$	41,108
	The aggregate intrinsic value of options exercised was $0.8 million for the three months ended June 30, 2014. The total fair value of options vested during the three months ended June 30, 2014 was $2.2 million.
	The remaining unrecognized stock-based compensation expense for unvested stock option awards at June 30, 2014 was approximately $5.9 million, net of forfeitures, and the weighted-average period over which this cost will be recognized is 2.6 years.
	The Company estimates the fair value of each stock option granted at the grant date using the Black-Scholes option valuation model. The weighted average grant-date fair value for options granted during the nine months ended June 30, 2014 and 2013 was $8.78 and $9.68 per share, respectively.
	The fair value of options granted during the three months ended June 30, 2014 and 2013 were calculated using the following weighted average assumptions:
		Three Months Ended
		June 30,
		2014			2013
	Risk-free interest rate		1.57	%		0.85	%
	Expected option life (years)		4.19			4.26
	Expected volatility		49.4	%		51.9	%
	The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for a term consistent with the expected life of the stock options. Volatility assumptions are calculated based on the historical volatility of the Company’s stock and adjustments for factors not reflected in historical volatility that may be more indicative of future volatility. The Company estimates the expected term of options based on historical exercise experience and estimates of future exercises of unexercised options. An expected dividend yield of zero is used in the option valuation model because the Company does not pay cash dividends and does not expect to pay any cash dividends in the foreseeable future. The Company estimates forfeitures based on an analysis of actual historical forfeitures, adjusted to reflect that historical forfeitures may not be indicative of forfeitures in the future.
	Restricted Stock and Restricted Stock Units
	In addition to stock option grants, the Company also has the ability to grant restricted stock and restricted stock units. Similar to stock options, these restricted stock and restricted stock unit grants are subject to certain vesting criteria. The following table summarizes the activity for the three months ended June 30, 2014:
		Number of			Weighted
		Shares			Average
					Grant Date
					Fair Value
		(in thousands)			(per share)
	Outstanding at April 1, 2014		1,174		$	21.37
	Granted		610			21.55
	Vested		(429	)		20.51
	Forfeited		(113	)		23.13
	Outstanding at June 30, 2014		1,242		$	21.59
	The remaining unrecognized compensation expense for outstanding restricted stock awards and restricted stock units, including performance-based awards, as of June 30, 2014 was $18.5 million and the weighted-average period over which this cost will be recognized is 2.2 years.
	The weighted average grant-date fair value for restricted stock and restricted stock units granted during the three months ended June 30, 2014 and 2013 was $21.55 and $23.15 per share, respectively. The total fair value of restricted stock and restricted stock units vested during the three months ended June 30, 2014 and 2013 was $8.8 million and $5.7 million, respectively.
	Performance Based Awards
	Included in the restricted stock and restricted stock units activity discussed above are certain awards that vest subject to certain performance-based criteria.
	In May 2014, performance-based awards of restricted stock units for the potential issuance of 379,752 shares of common stock were issued to certain executive officers and employees, all of which vest upon achievement of prescribed service milestones by the award recipients and performance milestones by the Company. As of June 30, 2014, the Company is recognizing compensation expense based on the probable outcome related to the prescribed performance targets on the outstanding awards.
	In May 2013, performance-based awards of restricted stock units for the potential issuance of 268,988 shares of common stock were issued to certain executive officers and employees, all of which vest upon achievement of prescribed service milestones by the award recipients and performance milestones by the Company. As of June 30, 2014, the Company has met the prescribed performance milestones for these awards. These awards are still subject to service requirements for vesting for these employees and the compensation expense is being recognized accordingly.
	In May 2012, performance-based awards of restricted stock units for the potential issuance of 195,188 shares of common stock were issued to certain executive officers and employees of the Company, all of which will vest upon achievement of prescribed service milestones by the award recipients and performance milestones by the Company. As of June 30, 2014, the Company has met the prescribed performance milestones for these awards. These awards are still subject to service requirements for vesting for these employees and the compensation expense is being recognized accordingly.
In May 2011 and June 2011, performance-based awards of restricted stock units for the potential issuance of 284,000 shares of common stock were issued to certain executive officers and members of the senior management of the Company, which vest upon achievement of prescribed service milestones by the award recipients and performance milestones by the Company. As of June 30, 2014, the Company has met the prescribed milestones for 234,000 shares underlying these awards and recorded all related stock compensation expense. In March 2014, the Company modified the performance condition on the remaining 50,000 restricted stock units. As of June 30, 2014, the Company believes that it is probable that the prescribed performance milestones will be met on these restricted stock units and the compensation expense is being recognized accordingly.
During the three months ended June 30, 2014, the Company has recorded $1.6 million in stock-based compensation expense for equity awards in which the prescribed performance milestones have been achieved or are probable of being achieved. The remaining unrecognized compensation expense related to these equity awards at June 30, 2014 is $9.4 million based on the Company’s current assessment of probability of achieving the performance milestones. The weighted-average period over which this cost will be recognized is 2.1 years.

Income_Taxes

Income Taxes	3 Months Ended
	Jun. 30, 2014
Income Taxes	'
	Note 8. Income Taxes
	Deferred income taxes are recognized for the tax consequences in future years of differences between the tax basis of assets and liabilities and their financial reporting amounts at each fiscal year end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce net deferred tax assets to the amount that is more likely than not to be realized.
	The Company regularly assesses its ability to realize its deferred tax assets. Assessing the realization of deferred tax assets requires significant management judgment. In determining whether its deferred tax assets are more likely than not realizable, the Company evaluated all available positive and negative evidence, and weighted the evidence based on its objectivity. Evidence the Company considered included, its history of net operating losses incurred for most of its existence, expiration of various federal and state attributes, the uncertainty relative to the Department of Justice and Office of Inspector General investigations of the Company and the Company’s Pre-Market Approval, or PMA, application with the U.S. Food and Drug Administration, or FDA, for its Impella products, the Company’s expansion into new markets, such as Japan, the government reimbursement environment for the Company’s products, the Company’s profitability for recent years and uncertainties around the Company’s forecasted profit before tax for fiscal 2015. Based on the review of all available evidence, the Company determined that the objectively verifiable negative evidence outweighed the positive evidence and it recorded a valuation allowance to reduce its deferred tax assets to the amount that is more likely than not to be realizable as of June 30, 2014. The Company will continue to assess the level of the valuation allowance required. If sufficient positive evidence exists in future periods to support a release of some or all of the valuation allowance, such a release would likely have a material impact on its results of operations.
	As of June 30, 2014, the Company has accumulated a net deferred tax liability of $6.6 million which is the result of the difference in accounting for the Company’s goodwill, which is amortizable over 15 years for tax purposes but not amortizable for book purposes. The net deferred tax liability cannot be offset against the Company’s deferred tax assets since it relates to an indefinite-lived asset and is not anticipated to reverse in the same period.
	The Company and its subsidiaries are subject to U.S. federal income tax, as well as income tax of multiple state and foreign jurisdictions. The Company has accumulated significant losses since its inception in 1981. All tax years remain subject to examination by major tax jurisdictions, including the federal government and the Commonwealth of Massachusetts. However, because the Company has net operating loss and tax credit carryforwards which may be utilized in future years to offset taxable income, those years may also be subject to review by relevant taxing authorities if the carryforwards are utilized.

Commitments_and_Contingencies

Commitments and Contingencies	3 Months Ended
	Jun. 30, 2014
Commitments and Contingencies	'
	Note 9. Commitments and Contingencies
	Commitments
	In July 2013, the Company entered into a lease agreement to continue renting its existing space in Aachen, Germany through July 31, 2023. The building serves as the Company’s European headquarters and houses most of the manufacturing operations for its Impella product line. The lease payments are approximately 34,500€ (euro) (approximately U.S. $47,000 at June 30, 2014 exchange rates) per month.
	In February 2014, the Company entered into a lease agreement to continue renting its existing space in Danvers, Massachusetts through February 28, 2021. Monthly rent is as follows:
		•	The base rent for March 2014 through April 2014 was $66,000 per month; and
		•	The base rent for May 2014 through February 2016 is $74,050 per month; and
		•	The base rent for March 2016 through February 2018 will be $70,750 per month; and
		•	The base rent for March 2018 through February 2021 will be $72,750 per month.
	License agreement
	In April 2014, the Company entered into an exclusive license agreement with Opsens, Inc. for the rights to certain optical sensor technologies in the field of cardio-circulatory assist devices. The Company made a $1.5 million upfront payment upon execution of the agreement and agreed to make additional payments of up to $4.5 million upon the achievement of certain development milestones.
	Litigation
	From time to time, the Company is involved in legal and administrative proceedings and claims of various types. In some actions, the claimants seek damages, as well as other relief, which, if granted, would require significant expenditures. The Company records a liability in its consolidated financial statements for these matters when a loss is known or considered probable and the amount can be reasonably estimated. The Company reviews these estimates each accounting period as additional information is known and adjusts the loss provision when appropriate. If a matter is both probable to result in liability and the amounts of loss can be reasonably estimated, the Company estimates and discloses the possible loss or range of loss. If the loss is not probable or cannot be reasonably estimated, a liability is not recorded in its consolidated financial statements.
	On October 26, 2012, the Company was informed that the United States Attorney’s Office for the District of Columbia is conducting an investigation that is focused on the Company’s marketing and labeling of the Impella 2.5. On October 31, 2012, the Company accepted service of a subpoena related to this investigation seeking documents related to the Impella 2.5. The Company believes that is has substantially complied with the subpoena and has submitted the requested documents to the United States Attorney’s Office. On September 13, 2013, the Company entered into a tolling agreement with the United States Attorney’s Office, pursuant to which the Company and the United States Attorney’s Office mutually agreed to toll the applicable statutes of limitations for all criminal, civil and administrative offenses and violations that could be charged or claimed against the Company as of that date until June 2, 2014. On May 27, 2014, the Company executed an extension of the tolling agreement through February 2, 2015. The investigation is ongoing, however, the Company is unable to predict the ultimate outcome or determine whether a liability has been incurred or make an estimate of the reasonably possible liability, if any, that could result from any unfavorable outcome associated with this inquiry. The Company has incurred significant expenses related to this investigation and expects to continue to incur additional expenses in the future.
	On November 16 and 19, 2012, two purported class action complaints were filed against the Company and certain of its officers in the U.S. District Court for the District of Massachusetts by alleged purchasers of its common stock, on behalf of themselves and persons or entities that purchased or acquired securities of the Company between August 5, 2011 and October 31, 2012. The complaints alleged that the defendants violated the federal securities laws in connection with disclosures related to the FDA and the marketing and labeling of the Company’s Impella 2.5 product and seek damages in an unspecified amount. The Court consolidated these complaints and a consolidated amended complaint was filed by the plaintiffs on May 20, 2013. On July 8, 2013, the Company filed a motion to dismiss the consolidated class action. Oral arguments on the Company’s motion to dismiss were conducted before the presiding district court judge on September 18, 2013. On April 10, 2014, the U.S. District Court entered an order granting our motion and dismissed the consolidated and amended complaint. On May 9, 2014, the plaintiffs filed a notice of appeal, and subsequently filed their appellate brief with the U.S. Court of Appeals for the First Circuit on July 16, 2014. The appeal process remains ongoing.
	On February 4, 2013, an alleged stockholder of the Company filed a derivative action on the Company’s behalf against each of the Company’s directors in the U.S. District Court for the District of Massachusetts. The complaint alleged that the directors breached their fiduciary duties to the Company and its stockholders in connection with disclosures related to the FDA and the marketing and labeling of its Impella 2.5 product and sought damages in an unspecified amount. On March 22, 2013, the Company filed a motion to dismiss the derivative action. On June 21, 2013, the District Court granted the Company’s motion to dismiss. The plaintiff appealed the dismissal to the U.S. Court of Appeals for the First Circuit. Oral argument was conducted before the appellate court on February 5, 2014, and the U.S. Court of Appeals for the First Circuit affirmed the District Court’s Order of Dismissal in a written opinion issued on June 10, 2014.
	On April 25, 2014, the Company received a subpoena from the Boston regional office of the United States Department of Health and Human Services, or HHS, Office of Inspector General requesting materials relevant to the Company’s reimbursement of expenses and remuneration to healthcare providers for a six month period from July 2012 through December 2012. The Office of Inspector General has informed the Company that the subpoena currently relates to a civil investigation. The Company believes that it has substantially complied with the subpoena and has submitted the requested documents to HHS.
	The Company is unable to estimate its potential liability with respect to the Department of Justice investigation, the Office of Inspector General’s investigation and the appeal of the dismissal of the purported class action claim. There are numerous factors that make it difficult to meaningfully estimate possible loss or range of loss at this stage of the investigation and lawsuits, including that: the proceedings are in relatively early stages, there are significant factual and legal issues to be resolved, information obtained or rulings made during any lawsuits or investigations could affect the methodology for calculation. In addition, with respect to claims where damages are the requested relief, no amount of loss or damages has been specified. Therefore, the Company is unable at this time to estimate its possible losses and accordingly, no adjustment has been made to the financial statements to reflect the outcome of these uncertainties.

Segment_and_Enterprise_Wide_Di

Segment and Enterprise Wide Disclosures	3 Months Ended
	Jun. 30, 2014
Segment and Enterprise Wide Disclosures	'
	Note 10. Segment and Enterprise Wide Disclosures
	The Company operates in one business segment—the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company’s chief operating decision maker (determined to be the Chief Executive Officer) does not manage any part of the Company separately, and the allocation of resources and assessment of performance are based on the Company’s consolidated operating results. Approximately 65% and 74% of the Company’s total consolidated assets are located within the U.S. as of June 30, 2014 and March 31, 2014, respectively. The remaining assets are located primarily in Germany and include goodwill of $37.7 million and $35.4 million at June 30, 2014 and March 31, 2014, respectively, associated with the Impella acquisition in May 2005. Total assets outside of the U.S. excluding goodwill amounted to 17% and 8% of total consolidated assets as of June 30, 2014 and March 31, 2014, respectively. International sales (sales outside the U.S. and primarily in Europe) accounted for 11% and 8% of total revenue for the three months ended June 30, 2014 and 2013, respectively.

Subsequent_Events

Subsequent Events	3 Months Ended
	Jun. 30, 2014
Subsequent Events	'
	Note 11. Subsequent Events
	Acquisition of ECP Entwickslungsgesellschaft mbH
	On July 1, 2014, the Company’s wholly-owned German subsidiary, Abiomed Europe GmbH (“Abiomed Europe”) and the Company, entered into a share purchase agreement with Syscore GmbH, a limited liability company incorporated in Germany (“Syscore”), providing for the acquisition of all of the issued shares of ECP Entwicklungsgesellschaft GmbH, a limited liability company incorporated in Germany (“ECP”). ECP, based in Berlin, Germany, is engaged in research, development, prototyping and the pre-serial production of a percutaneous expandable catheter pump which increases blood circulation from the heart with an external drive shaft.
	The Company acquired ECP for $13.0 million in cash, with additional potential payouts up to a maximum of $15.0 million payable to Syscore based on the achievement of certain technical and commercial milestones. These milestone payments may be made, at the Company’s option, by a combination of cash or its common stock. The Company placed $1.3 million of the initial closing payment in escrow for the purpose of partially securing any amounts payable by Syscore as a result of the indemnification provisions in the agreement.
	ECP’s Acquisition of AIS GmbH Aachen Innovative Solutions
	On July 1, 2014, in connection with the Company’s acquisition of ECP, ECP acquired all of the issued shares of AIS GmbH Aachen Innovative Solutions (“AIS”), a limited liability company incorporated in Germany. AIS, based in Aachen, Germany, holds certain intellectual property useful to ECP’s business, and, prior to being acquired by ECP, had licensed such intellectual property to ECP. The purchase price for the acquisition of AIS’s shares was $2.8 million in cash and the acquisition closed immediately prior to Abiomed Europe’s acquisition of ECP.
	The acquisitions will be accounted for as a business combination which requires that the consideration exchanged and net assets acquired be recorded in the Company’s financial statements at their respective fair values at the date of acquisition. The Company will include the financial results of ECP and AIS in its consolidated financial statements commencing July 1, 2014. Based upon the timing of the acquisitions subsequent to the Company’s first quarter of fiscal 2015, the initial accounting for the business combination is incomplete at the time of filing this report. The Company is currently in the process of determining the purchase accounting impact of the acquisitions. As a result, the Company is unable to provide amounts recognized as of the acquisition date for major classes of assets and liabilities acquired and certain required disclosures. If material, the Company will include this in future financial statements.
	To date through June 30, 2014, the Company has incurred $0.7 million in transaction costs related to these acquisitions, which have been recorded in general and administrative expenses.

Nature_of_Business_and_Basis_o1

Nature of Business and Basis of Preparation (Policies)	3 Months Ended
	Jun. 30, 2014
Recent Accounting Pronouncements	'
	Recent Accounting Pronouncements
	In May 2014, the Financial Accounting Standards Board issued Accounting Standards Update (ASU) 2014-09, Revenue from Contracts with Customers to provide updated guidance on revenue recognition. ASU 2014-09 requires a company to recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In doing so, companies may need to use more judgment and make more estimates than under today’s guidance. These may include identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. ASU 2014-09 is effective for the Company in the first quarter of fiscal 2017. Early adoption is not permitted. The Company is currently evaluating the impact of adopting ASU 2014-09 on its consolidated financial statements.

Net_Loss_Income_Per_Share_Tabl

Net (Loss) Income Per Share (Tables)	3 Months Ended
	Jun. 30, 2014
Computation of Basic and Diluted Net (Loss) Income Per Share	'
	The Company’s basic and diluted net (loss) income per share for the three months ended June 30, 2014 and 2013 were as follows (in thousands, except per share data):
		Three Months Ended
		June 30,
		2014			2013
	Basic Net (Loss) Income Per Share
	Net loss	$	(1,709	)	$	(1,723	)
	Weighted average shares used in computing basic net loss per share		40,062			38,678
	Net loss per share - basic	$	(0.04	)	$	(0.04	)
		Three Months Ended
		June 30,
		2014			2013
	Diluted Net (Loss) Income Per Share
	Net loss	$	(1,709	)	$	(1,723	)
	Weighted average shares used in computing basic net loss per share		40,062			38,678
	Effect of dilutive securities		—			—
	Weighted average shares used in computing diluted net loss per share		40,062			38,678
	Net loss per share - diluted	$	(0.04	)	$	(0.04	)

Marketable_Securities_and_Fair1

Marketable Securities and Fair Value Measurements (Tables)	3 Months Ended
	Jun. 30, 2014
Marketable Securities	'
	The Company’s marketable securities at June 30, 2014 and March 31, 2014 are invested in the following:
		Amortized		Gross		Gross			Fair Market
		Cost		Unrealized		Unrealized			Value
				Gains		Losses
		(in $000’s)
	At June 30, 2014:
	US Treasury securities	$	19,486	$	—	$	—		$	19,486
	Short-term government-backed securities		32,963		11		(2	)		32,972
	Long-term government-backed securities		33,758		11		(9	)		33,760
		$	86,207	$	22	$	(11	)	$	86,218
Financial Instruments Recorded at Fair Value	'
	The following table presents the Company’s financial instruments recorded at fair value in the consolidated balance sheet, classified according to the three categories described above:
		Level 1		Level 2		Level 3			Total
		(in $000’s)
	At June 30, 2014:
	U.S. Treasury securities		—	$	19,486		—		$	19,486
	Short-term government-backed securities		—		32,972		—			32,972
	Long-term government-backed securities		—		33,760		—			33,760
			—	$	86,218		—		$	86,218

Inventories_Tables

Inventories (Tables)	3 Months Ended
	Jun. 30, 2014
Components of Inventories	'
	The components of inventories are as follows:
		June 30,		March 31,
		2014		2014
		(in $000’s)
	Raw materials and supplies	$	6,534	$	6,414
	Work-in-progress		6,295		6,261
	Finished goods		1,091		1,273
		$	13,920	$	13,948

Goodwill_Tables

Goodwill (Tables)	3 Months Ended
	Jun. 30, 2014
Goodwill Activity	'
	The goodwill activity for the three months ended June 30, 2014 is as follows:
		(in $000’s)
	Balance at March 31, 2014	$	37,990
	Exchange rate impact		(296	)
	Balance at June 30, 2014	$	37,694

Accrued_Expenses_Tables

Accrued Expenses (Tables)	3 Months Ended
	Jun. 30, 2014
Accrued Expenses	'
	Accrued expenses consist of the following:
		June 30,		March 31,
		2014		2014
		(in $000’s)
	Employee compensation	$	11,798	$	11,967
	Research and development		1,403		1,587
	Sales and income taxes		1,215		1,445
	Professional, legal and accounting fees		998		1,304
	Warranty		813		794
	Other		788		802
		$	17,015	$	17,899

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	3 Months Ended
	Jun. 30, 2014
Stock-Based Compensation Recognized	'
	The following table summarizes stock-based compensation expense by financial statement line item in the Company’s consolidated statements of operations for the three months ended June 30, 2014 and 2013:
		Three Months Ended
		June 30,
		2014			2013
		(in $000’s)
	Cost of product revenue	$	209		$	208
	Research and development		853			745
	Selling, general and administrative		3,228			2,968
		$	4,290		$	3,921
Components of Stock-Based Compensation	'
	The components of stock-based compensation for the three months ended June 30, 2014 and 2013 were as follows:
		Three Months Ended
		June 30,
		2014			2013
		(in $000’s)
	Restricted stock units and awards	$	3,420		$	2,936
	Stock options		799			925
	Employee stock purchase plan		71			60
		$	4,290		$	3,921
Summary of Stock Option Activity	'
	The following table summarizes the stock option activity for the three months ended June 30, 2014:
								Weighted
		Shares			Weighted			Average		Aggregate
		Underlying			Average			Remaining		Intrinsic
		Options			Exercise			Contractual		Value
		(in thousands)			Price			Term (years)		(in thousands)
	Outstanding at April 1, 2014		3,492		$	13.27			4.92
	Granted		256			21.55
	Exercised		(67	)		9.99
	Cancelled and expired		(3	)		17.67
	Outstanding at June 30, 2014		3,678		$	13.9			5.08	$	41,412
	Exercisable at June 30, 2014		2,938		$	11.93			4.11	$	38,802
	Options vested and expected to vest at June 30, 2014		3,614		$	13.78			5.01	$	41,108
Weighted-Average Assumptions Used to Calculate Fair Value of Options Granted	'
	The fair value of options granted during the three months ended June 30, 2014 and 2013 were calculated using the following weighted average assumptions:
		Three Months Ended
		June 30,
		2014			2013
	Risk-free interest rate		1.57	%		0.85	%
	Expected option life (years)		4.19			4.26
	Expected volatility		49.4	%		51.9	%
Summary of Restricted Stock and Restricted Stock Units Activity	'
	The following table summarizes the activity for the three months ended June 30, 2014:
		Number of			Weighted
		Shares			Average
					Grant Date
					Fair Value
		(in thousands)			(per share)
	Outstanding at April 1, 2014		1,174		$	21.37
	Granted		610			21.55
	Vested		(429	)		20.51
	Forfeited		(113	)		23.13
	Outstanding at June 30, 2014		1,242		$	21.59

Computation_of_Basic_and_Dilut

Computation of Basic and Diluted Net (Loss) Income Per Share (Detail) (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
Basic Net (Loss) Income Per Share	'	'
Net (loss) income	($1,709)	($1,723)
Weighted average shares used in computing basic net (loss) income per share	40,062	38,678
Net (loss) income per share - basic	($0.04)	($0.04)
Diluted Net (Loss) Income Per Share	'	'
Net (loss) income	($1,709)	($1,723)
Weighted average shares used in computing basic net (loss) income per share	40,062	38,678
Effect of dilutive securities	0	0
Weighted average shares used in computing diluted net (loss) income per share	40,062	38,678
Net (loss) income per share - diluted	($0.04)	($0.04)

Net_Loss_Income_Per_Share_Addi

Net (Loss) Income Per Share - Additional Information (Detail)	3 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Stock Options	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Shares excluded from the calculation of diluted weighted average shares outstanding	3,678,000	4,326,000
Restricted Stock and Restricted Stock Units	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Shares excluded from the calculation of diluted weighted average shares outstanding	1,242,000	1,168,000

Investable_Marketable_Securiti

Investable Marketable Securities (Detail) (USD $)	Jun. 30, 2014	Mar. 31, 2014
In Thousands, unless otherwise specified
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Fair Market Value	$86,218	$97,424
US Treasury Securities	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Fair Market Value	19,486	31,487
US Government-sponsored Enterprises Debt Securities | Short-term Investments	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Fair Market Value	32,972	24,176
US Government-sponsored Enterprises Debt Securities | Long-term Investments	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Fair Market Value	33,760	41,761
Level 2	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Amortized Cost	86,207	97,440
Gross Unrealized Gains	22	14
Gross Unrealized Losses	-11	-30
Fair Market Value	86,218	97,424
Level 2 | US Treasury Securities	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Amortized Cost	19,486	31,487
Fair Market Value	19,486	31,487
Level 2 | US Government-sponsored Enterprises Debt Securities | Short-term Investments	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Amortized Cost	32,963	24,174
Gross Unrealized Gains	11	6
Gross Unrealized Losses	-2	-4
Fair Market Value	32,972	24,176
Level 2 | US Government-sponsored Enterprises Debt Securities | Long-term Investments	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Amortized Cost	33,758	41,779
Gross Unrealized Gains	11	8
Gross Unrealized Losses	-9	-26
Fair Market Value	$33,760	$41,761

Financial_Instruments_Recorded

Financial Instruments Recorded at Fair Value (Detail) (USD $)	Jun. 30, 2014	Mar. 31, 2014
In Thousands, unless otherwise specified
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities, fair value disclosure	$86,218	$97,424
US Treasury Securities	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities, fair value disclosure	19,486	31,487
US Government-sponsored Enterprises Debt Securities | Short-term Investments	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities, fair value disclosure	32,972	24,176
US Government-sponsored Enterprises Debt Securities | Long-term Investments	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities, fair value disclosure	33,760	41,761
Level 2	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities, fair value disclosure	86,218	97,424
Level 2 | US Treasury Securities	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities, fair value disclosure	19,486	31,487
Level 2 | US Government-sponsored Enterprises Debt Securities | Short-term Investments	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities, fair value disclosure	32,972	24,176
Level 2 | US Government-sponsored Enterprises Debt Securities | Long-term Investments	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities, fair value disclosure	$33,760	$41,761

Components_of_Inventories_Deta

Components of Inventories (Detail) (USD $)	Jun. 30, 2014	Mar. 31, 2014
In Thousands, unless otherwise specified
Inventory [Line Items]	'	'
Raw materials and supplies	$6,534	$6,414
Work-in-progress	6,295	6,261
Finished goods	1,091	1,273
Inventories	$13,920	$13,948

Inventories_Additional_Informa

Inventories - Additional Information (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
Inventory [Line Items]	'	'
Write-down of inventory	$206	$207

Goodwill_Additional_Informatio

Goodwill - Additional Information (Detail) (USD $)	Jun. 30, 2014	Mar. 31, 2014
In Thousands, unless otherwise specified
Goodwill [Line Items]	'	'
Goodwill	$37,694	$37,990
Accumulated impairment loss, goodwill	$0	'

Goodwill_Activity_Detail

Goodwill Activity (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014
Goodwill [Line Items]	'
Beginning Balance	$37,990
Exchange rate impact	-296
Ending Balance	$37,694

Accrued_Expenses_Detail

Accrued Expenses (Detail) (USD $)	Jun. 30, 2014	Mar. 31, 2014
In Thousands, unless otherwise specified
Payables and Accruals [Abstract]	'	'
Employee compensation	$11,798	$11,967
Research and development	1,403	1,587
Sales and income taxes	1,215	1,445
Professional, legal and accounting fees	998	1,304
Warranty	813	794
Other	788	802
Accrued expenses	$17,015	$17,899

StockBased_Compensation_Recogn

Stock-Based Compensation Recognized (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Stock-based compensation	$4,290	$3,921
Cost of product revenue	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Stock-based compensation	209	208
Research and development	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Stock-based compensation	853	745
Selling, general and administrative	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Stock-based compensation	$3,228	$2,968

Components_of_StockBased_Compe

Components of Stock-Based Compensation (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Stock-based compensation	$4,290	$3,921
Restricted stock units and awards	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Stock-based compensation	3,420	2,936
Stock Options	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Stock-based compensation	799	925
Employee Stock Purchase Plan	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Stock-based compensation	$71	$60

Summary_of_Stock_Option_Activi

Summary of Stock Option Activity (Detail) (USD $)	3 Months Ended	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Jun. 30, 2014	Mar. 31, 2014
Options	'	'
Outstanding at April 1, 2014	3,492	'
Granted	256	'
Exercised	-67	'
Cancelled and expired	-3	'
Outstanding at June 30, 2014	3,678	3,492
Exercisable at June 30, 2014	2,938	'
Options vested and expected to vest at end of year	3,614	'
Weighted-Average Exercise Price	'	'
Outstanding at April 1, 2014	$13.27	'
Granted	$21.55	'
Exercised	$9.99	'
Cancelled and expired	$17.67	'
Outstanding at June 30, 2014	$13.90	$13.27
Exercisable at June 30, 2014	$11.93	'
Options vested and expected to vest at June 30, 2014	$13.78	'
Weighted-Average Remaining Contractual Term (years)	'	'
Outstanding	'5 years 29 days	'4 years 11 months 1 day
Exercisable at June 30, 2014	'4 years 1 month 10 days	'
Options vested and expected to vest at June 30, 2014	'5 years 4 days	'
Aggregate Intrinsic Value	'	'
Outstanding at June 30, 2014	$41,412	'
Exercisable at June 30, 2014	38,802	'
Options vested and expected to vest at June 30, 2014	$41,108	'

StockBased_Compensation_Additi

Stock-Based Compensation - Additional Information (Detail) (USD $)

3 Months Ended

1 Months Ended

3 Months Ended

1 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2011

31-May-11

Jun. 30, 2014

31-May-14

31-May-13

31-May-12

Stock Options

Stock Options

Restricted Stock and Restricted Stock Units

Restricted Stock and Restricted Stock Units

Performance Based Restricted Stock and Restricted Stock Units

Performance Based Restricted Stock and Restricted Stock Units

Performance Based Restricted Stock and Restricted Stock Units

Performance Based Restricted Stock and Restricted Stock Units

Performance Based Restricted Stock and Restricted Stock Units

Performance Based Restricted Stock and Restricted Stock Units

Share Based Awards

Share Based Awards

Share Based Awards

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Aggregate intrinsic value of options exercised in period

$800,000

'

'

'

'

'

'

'

'

'

'

'

Fair value of options vested in period

2,200,000

'

'

'

'

'

'

'

'

'

'

'

Unrecognized stock-based compensation expense

'

'

5,900,000

'

18,500,000

'

'

'

9,400,000

'

'

'

Unrecognized stock-based compensation expense, weighted-average recognition period

'

'

'2 years 7 months 6 days

'

'2 years 2 months 12 days

'

'

'

'2 years 1 month 6 days

'

'

'

Weighted average grant-date fair value for options granted

$8.78

$9.68

'

'

'

'

'

'

'

'

'

'

Expected dividend yield

0.00%

'

'

'

'

'

'

'

'

'

'

'

Weighted average grant-date fair value for restricted stock and restricted stock units granted

'

'

'

'

$21.55

$23.15

'

'

'

'

'

'

Fair value of restricted stock and restricted stock units vested in period

'

'

'

'

8,800,000

5,700,000

'

'

'

'

'

'

Shares of award granted

'

'

'

'

610,000

'

284,000

284,000

'

379,752

268,988

195,188

Shares of award granted, performance target met

'

'

'

'

'

'

'

'

234,000

'

'

'

Shares of award granted, it is probable that the prescribed performance targets will be met

'

'

'

'

'

'

'

'

50,000

'

'

'

Stock-based compensation

$4,290,000

$3,921,000

$799,000

$925,000

'

'

'

'

$1,600,000

'

'

'

Weighted_Average_Assumptions_U

Weighted Average Assumptions Used to Calculate Fair Value of Options Granted (Detail)	3 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]	'	'
Risk-free interest rate	1.57%	0.85%
Expected option life (years)	'4 years 2 months 9 days	'4 years 3 months 4 days
Expected volatility	49.40%	51.90%

Summary_of_Restricted_Stock_an

Summary of Restricted Stock and Restricted Stock Units Activity (Detail) (Restricted Stock and Restricted Stock Units, USD $)	3 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Restricted Stock and Restricted Stock Units	'	'
Number of Shares	'	'
Beginning Balance	1,174,000	'
Granted	610,000	'
Vested	-429,000	'
Forfeited	-113,000	'
Ending Balance	1,242,000	'
Weighted Average Grant Date Fair Value	'	'
Beginning Balance	$21.37	'
Granted	$21.55	$23.15
Vested	$20.51	'
Forfeited	$23.13	'
Ending Balance	$21.59	'

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Mar. 31, 2014
Income Taxes [Line Items]	'	'
Net deferred tax liability	$6,640	$6,415
Amortization period of deferred tax liability (years)	'15 years	'

Commitments_and_Contingencies_

Commitments and Contingencies - Additional Information (Detail)	Apr. 30, 2014	Jun. 30, 2014	Jun. 30, 2014	Jun. 30, 2014	Jun. 30, 2014	Jul. 31, 2013	Jun. 30, 2014	Jun. 30, 2014
	USD ($)	For March 2014 through April 2014	For May 2014 through February 2016	For March 2016 through February 2018	For March 2018 through February 2021	Europe	Europe	Europe
		USD ($)	USD ($)	USD ($)	USD ($)	Lease Agreements	Lease Agreements	Lease Agreements
							USD ($)	EUR (€)
Commitments and Contingencies [Line Items]	'	'	'	'	'	'	'	'
Facilities leases, base rent per month	'	$66,000,000	$74,050,000	$70,750,000	$72,750,000	'	$47,000,000	€ 34,500,000
Lease, expiration date	'	'	'	'	'	31-Jul-23	'	'
License agreement, upfront payment	1,500,000	'	'	'	'	'	'	'
License agreement, maximum agreed additional payments upon achievement of development milestones	$4,500,000	'	'	'	'	'	'	'

Segment_and_Enterprise_Wide_Di1

Segment and Enterprise Wide Disclosures - Additional Information (Detail) (USD $)	3 Months Ended						3 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Mar. 31, 2014	Jun. 30, 2014	Mar. 31, 2014	Jun. 30, 2014	Mar. 31, 2014	Jun. 30, 2014	Jun. 30, 2013
	Segment		United States	United States	Europe	Europe	International	International
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'
Number of business segments	1	'	'	'	'	'	'	'
Percentage of total consolidated assets	'	'	65.00%	74.00%	'	'	'	'
Goodwill	$37,694	$37,990	'	'	$37,700	$35,400	'	'
Percentage of total consolidated assets, excluding goodwill	'	'	'	'	17.00%	8.00%	'	'
Percentage of total product revenue	'	'	'	'	'	'	11.00%	8.00%

Subsequent_Events_Additional_I

Subsequent Events - Additional Information (Detail) (USD $)	3 Months Ended	0 Months Ended		0 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014	Jul. 01, 2014	Jul. 01, 2014	Jul. 01, 2014
		Subsequent Event	Subsequent Event	Subsequent Event
		ECP Entwicklungsgesellschaft GmbH	ECP Entwicklungsgesellschaft GmbH	AIS GmbH Aachen Innovative Solutions
Subsequent Event [Line Items]	'	'	'	'
Business acquisition, date of acquisition agreement	'	1-Jul-14	'	'
Payment for business acquisition, cash paid	'	$13	'	$2.80
Potential payouts payments	'	'	15	'
Escrow for purpose of partially securing any amounts payable by indemnification provisions in agreement	'	'	1.3	'
Acquisition transaction costs	$0.70	'	'	'